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Introduction
In health, peptides released from the stomach and/or 
intestine modulate motility, secretion, absorption, 
mucosal growth and immune function of the gastro-
intestinal tract [1]. Th  ese hormones also have eﬀ  ects 
outside the gastrointestinal tract, particularly in relation 
to the regulation of energy intake and glycaemia [1]. In 
critically ill patients, both the prevalence and magnitude 
of disordered gastrointestinal and metabolic function are 
substantial [2]. Moreover, many of these abnormalities 
are associated with poor outcomes [3]. It is now apparent 
that a number of gastrointestinal hormones mediate, or 
have the potential to mediate, some of the functional 
abnormalities that occur in the critically ill, either via 
increased or decreased secretion. Th  e present review 
focuses on the abnormalities in gastrointestinal function 
and glucose metabolism that occur in the critically ill, 
focuses on current understanding of the eﬀ  ects of gastro-
intestinal hormones in health and critical illness, and 
focuses on implications of the above for management and 
priorities for future research.
Gastrointestinal motility in critical illness
Abnormalities in gastrointestinal motor function have 
recently been described, and quantiﬁ  ed, in the critically 
ill using a number of measurement techniques not pre-
viously utilised in this cohort. Published studies are likely 
to have underestimated the prevalence and magnitude of 
these motor abnormalities, however, as – in our experi-
ence – patients with the most marked motor abnor  mali-
ties are often the most technically demanding to study.
In the critically ill, motility of the entire gastrointestinal 
tract may be aﬀ  ected. In an observational study at our 
centre, the tone of the lower oesophageal sphincter was 
markedly reduced in all 15 critically ill patients studied 
and is likely to increase the propensity for gastro-oeso-
phageal reﬂ  ux [4]. In patients that are sedated and venti-
lated, reﬂ  ux is regarded as a major cause of aspiration, 
and consequent ventilator-associated pneumonia [4].
Feed intolerance occurs in up to 50% of critically ill 
patients, predominately due to delayed gastric emptying, 
and is considered a risk factor for adverse sequelae, such 
as inadequate nutrition [3,5]. Th   e motor function of the 
both the proximal and/or distal stomach is disordered in 
~50% of critically ill patients and underlies the delayed 
gastric emptying (which may also contribute to a higher 
frequency, and volume, of gastro-oesophageal reﬂ  ux 
events) [6]. In health, the proximal stomach acts as a 
reser  voir for liquid feed. In critical illness, however, the 
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In health, hormones secreted from the gastrointestinal 
tract have an important role in regulating 
gastrointestinal motility, glucose metabolism and 
immune function. Recent studies in the critically ill have 
established that the secretion of a number of these 
hormones is abnormal, which probably contributes 
to disordered gastrointestinal and metabolic function. 
Furthermore, manipulation of endogenous secretion, 
physiological replacement and supra-physiological 
treatment (pharmacological dosing) of these hormones 
are likely to be novel therapeutic targets in this 
group. Fasting ghrelin concentrations are reduced 
in the early phase of critical illness, and exogenous 
ghrelin is a potential therapy that could be used to 
accelerate gastric emptying and/or stimulate appetite. 
Motilin agonists, such as erythromycin, are eff  ective 
gastrokinetic drugs in the critically ill. Cholecystokinin 
and peptide YY concentrations are elevated in both 
the fasting and postprandial states, and are likely to 
contribute to slow gastric emptying. Accordingly, there 
is a rationale for the therapeutic use of their antagonists. 
So-called incretin therapies (glucagon-like peptide-1 and 
glucose-dependent insulinotropic polypeptide) warrant 
evaluation in the management of hyperglycaemia in 
the critically ill. Exogenous glucagon-like peptide-2 (or 
its analogues) may be a potential therapy because of its 
intestinotropic properties.
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of nutrient is delayed and reduced [7]. Th  e  coordination, 
magnitude and frequency of contractions in the proximal 
and distal stomach are reduced, leading to decreased 
transpyloric ﬂ   ow of chyme [7,8]. Th  e interaction of 
nutrient with small-intestinal receptors (mediated, at 
least in part, via enterogastric hormones) is pivotal to the 
regulation of gastric emptying in health and critical 
illness. However, in the critically ill inhibitory small-
intestinal feed  back on gastric emptying appears to be 
substantially enhanced (Figure 1) [6].
Th  e  eﬀ  ects of critical illness on small-intestinal motility 
are poorly deﬁ  ned, although disorganisation of duodenal 
pressure waves occurs frequently, with increased retro-
grade activity and diminished propagation of antegrade 
pressure waves [9]. It is likely that some patients have 
slow small-intestinal transit, due to prolonged periods of 
quiescent motor activity, and that a proportion of 
patients, as a result of disordered burst-like motor 
activity, hav    e subsequent rapid transit. Th  is concept is 
supported by a study from Rauch and colleagues in which 
non-nutrient small-intestinal transit times in 16 
neurointensive care patients (admitted <4 days) were 
measured using video capsule technology. Th  ey  reported 
that median transit times were similar, albeit with greater 
inter-subject variability, to those in health [10]. Th  e  eﬀ  ect 
of critical illness on colonic motility is yet to be evaluated.
Gastrointestinal absorptive and immune function in the 
critically ill
Absorption of nutrient is substantially impaired in the 
critically ill (Figure 2) [11,12]. Th   e altered absorption may 
be a consequence of disordered transit of chyme and/or 
impaired mucosal function [12]. In addition, the epithe-
lial barrier function is impaired, with a consequent 
increase in gastrointestinal permeability, and a potential 
predisposition to translocation of enteric organisms, 
systemic infection and, hence, adverse outcomes [11,13].
Figure 1. Hormones aff  ecting gastric emptying in health and critical illness. Eff  ect of hormones on gastric emptying (GE) in health and their 
known fasting concentrations in the critically ill. CCK, cholecystokinin; GLP, glucagon-like peptide; ICU, intensive care unit; PYY, peptide YY.
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Hyperglycaemia is common in acute illness, even in those 
patients without pre-existing diabetes [14]. Th  e Leuven 
trial established that marked hyperglycaemia (blood 
glucose >12 mmol/l) is associated with poor outcomes in 
surgical intensive care unit patients [15]. Th  is  landmark 
study resulted in a paradigm shift in the management of 
glycaemia in the critically ill. Subsequent studies, how-
ever, reported that substantial hypoglycaemia (blood 
glucose <2.2 mmol/l) occurred frequently with intensive 
insulin therapy, and hypoglycaemia is also associated 
with adverse outcomes [16]. Hence, while the optimum 
blood glucose target in the critically ill remains uncertain 
[17], treatment of hyperglycaemia and avoidance of 
iatrogenic hypoglycaemia are priorities. Moreover, there 
is evidence that glycaemic variability, in addition to mean 
glucose, is deleterious [18]. Safer methods for the 
manage  ment of hyperglycaemia in the critically ill are 
therefore desirable.
Methods
We performed a comprehensive search, restricted to 
manuscr    ipts written in English, on MEDLINE/PubMed, 
from inception to 1 July 2009. We used both the following 
MeSH terms and combinations of these terms: gastro-
intestinal hormones, ghrelin, motilin, cholecystokinin, 
peptide YY, glucagon-like peptide-1, glucagon-like 
peptide-2, glucose-dependent insulinotropic polypeptide, 
incretins, critical illness, intensive care. In addition, we 
searched the bibliographies of retrieved articles manually.
Results and discussion
Th  e gastrointestinal hormones most likely to be of 
clinical signiﬁ  cance are reviewed. For each hormone, a 
summary of where the peptide is stored, stimuli for 
secretion and the location of receptors is provided. 
Studies relating to the potential physiological eﬀ  ects 
focus on the use of the speciﬁ  c antagonists. In addition, 
physiological replacement and pharmacological dosing 
studies are presented when relevant.
Ghrelin
Ghrelin is a 28-amino-acid peptide secreted primarily 
from the stomach during fasting [19]. Secretion is 
suppressed by meal ingestion, chieﬂ  y as a result of the 
interaction of nutrients with the small intestine [20]. Th  e 
magnitude of this suppression appears to be dependent 
on the length of small intestine exposed to nutrient [21], 
but not the energy load [22]. Fasting plasma ghrelin 
concentrations are inversely related to body weight, with 
relatively lower concentrations in obesity and higher 
concentrations in anorectic patients [23]. Receptors to 
ghrelin are distributed widely, including the hypothala-
mus, pituitary and stomach [24].
Studies using exogenous ghrelin (infused to replicate 
physiological fasting concentrations) indicate that ghrelin 
is an important acute stimulant of appetite [19]. Further-
more, treatment with an oral ghrelin mimetic for 2 years 
has been reported to increase fat-free body mass in older 
humans [25]. Exogenous ghrelin at supra-physiological 
concentrations accelerates gastric emptying in humans 
Figure 2. Absorption of carbohydrate is impaired in the critically ill. In nine critically ill patients (with normal gastric emptying (GE)) both 
peak and area under the curve (AUC) concentrations for plasma 3-O-methyl-glucose [3-OMG] (an index of glucose absorption) were markedly 
attenuated when compared with 19 healthy subjects. [3-OMG] AUC0–240 min: critically ill patients, 38.9 ± 11.4 mmol/l/min vs. healthy subjects, 
66.6 ± 16.8 mmol/l/min; P <0.001 (mean ± standard deviation). Reproduced from [12]. ICU, intensive care unit.
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[26-28]. Th   e ghrelin agonist, TZP-101, accelerates empty-
ing substantially in patients with gastroparesis [29]. 
TZP-101 has also been reported to reduce the post-
operative i    leus time in animals [30], and this may also be 
the case in humans (Dr G Kostuic, personal communi-
cation). Pharmacological doses of ghrelin also increase 
fasting blood glucose and suppress plasma insulin 
secretion [31].
Fasting plasma ghrelin concentrations are markedly 
reduced (>50%) in the early phase of critical illness, with 
suppression continuing up to day 28 post admission [32]. 
Th  e reduction in ghrelin secretion may play a role in 
delayed gastric emptying, weight loss and decreased 
appetite that all occur frequently in the critically ill. Th  e 
same investigators reported that there was an exaggerated 
suppression of plasma ghrelin in response to nutrient in 
patients post cardiac surgery (day 6), when compared 
with preoperative concentrations, or in healthy controls, 
and suggested this may contribute to early satiation in 
postoperative patients [33]. Th  e suppression of ghrelin 
(that is, change from fasting concentration), however, 
was apparent because of elevated fasting levels. While the 
increase in fasting concentrations in postoperative 
patients appears inconsistent with the ﬁ  ndings in critical 
illness, it is likely that 6 days after elective surgery, albeit 
major surgery, is not representative of the more profound 
changes in physiology that occur during critical illness.
Ghrelin (either physiological replacement or pharma-
co  logical doses) has not been evaluated as a therapy in 
critically ill patients. Exogenous ghrelin has, however, 
been reported to improve outcomes in patients with 
chronic organ failure. In open-label studies by Nagaya 
and colleagues, ghrelin was given for 3 weeks to patients 
with chronic lung disease or cardiac failure – with a 
consequent modest increase in exercise tolerance 
apparent with the intervention in both studies [34,35]. 
Th  e underlying mechanism(s) is likely to be via both 
growth hormone eﬀ  ects (skeletal muscle strength) and 
growth hormone-independent eﬀ  ects (appetite).
Motilin
Motilin is structurally related to ghrelin, and motilin 
receptors are located throughout the gastrointestinal 
tract [36]. Motilin secretion is stimulated during the 
interdigestive state, and the peak plasma motilin concen-
tration coincides with the onset of frequent gastro-
intestinal antegrade contractions (that is, phase III of the 
migrating motor complex) [37]. Exogenous motilin induces 
antegrade contractions in the stomach and, consequently, 
accelerates gastric emptying in health     and gastroparesis 
[38].
Because oral formulations allow easier administration 
in outpatients, nonpeptide motilin agonists (motilides) 
have been developed as prokinetic agents, rather than 
motilin itself. Erythromycin has the capacity to accelerate 
gastric emptying profoundly in both healthy individuals 
and ambulant patients with gastroparesis [39,40]. Th  e 
eﬀ  ect is attenuated by hyperglycaemia [41], however, and 
the response may not be sustained as a result of tachy-
phylaxis [42]. Motlilides have also been reported to 
increase lower oesophageal sphincter pressure [43] and 
to aﬀ  ect small-intestinal motility, such that intravenous 
erythromycin at doses ~3 mg/kg has been reported to 
slow small-intestinal transit [44,45].
Th  e  eﬀ  ect of critical illness on plasma concentrations of 
motilin is not known. Despite this, the gastrokinetic 
eﬀ  ects of motilides make them a suitable drug to improve 
feed tolerance in the critically ill [6]. While acceleration 
of gastric emptying may not improve fasting, or meal-
related, symptoms in ambulatory patients with gastro-
paresis, acceleration of the gastric emptying rate and, 
thereby, improving enteral feed tolerance is the primary 
outcome of relevance in the sedated critically ill patient, 
rather than symptom relief [6]. Accordingly, erythro-
mycin has been shown to be a potent gastrokinetic in the 
critically ill [46,47], although in ~60% of patients its 
eﬀ  ects are diminished within 7 days [46].
Cholecystokinin
Cholecystokinin (CCK) is stored in enteroendocrine cells 
in the duodenum and jejunum, and is secreted in 
response to the presence of fat, protein and, to a lesser 
degree, carbohydrate in the small intestine [48]. Th  e  use 
of speciﬁ  c antagonists, such as loxiglumide, has aﬀ  orded 
a greater understanding of the physiological actions of 
CCK on luminal motility, secretory function and appe-
tite. Appetite and energy intake are increased during 
loxiglumide infusion [49]. In the postprandial phase, 
CCK may reduce the lower oesophageal sphincter basal 
pressure and increase the frequency of transient lower 
oesophageal sphincter relaxations, with a consequent 
increase in the number of gastro-oesophageal reﬂ  ux 
events [50]. Endogenous CCK also slows gastric emptying 
in humans and may accelerate small-intestinal transit 
[51,52]. CCK is the principle physiological regulator of 
gallbladder contraction and augments pancreatic protein 
enzyme secretion, with both eﬀ   ects suppressed by 
loxiglu mide  [53].
In critically ill patients, fasting plasma CCK concen-
trations are approximately twice those of healthy controls, 
and nutrient-stimulated CCK concentrations are some 
1.5-fold greater [54]. Furthermore, fasting plasma CCK 
concentrations are higher in critically ill patients with 
delayed gastric emptying, when compared with those with 
normal emptying (Figure 3) [55]. Th   e reduction in appetite 
(and gastric emptying) that occurs in healthy ageing has 
been attributed, in part, to increased concentrations and/
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same satiety eﬀ  ect in the critically ill, and CCK may be a 
mediator of slow gastric emptying in this group. Studies 
involving administration of a CCK antagonist are required 
to evaluate this hypothesis.
Th   e mechanism(s) underlying exaggerated CCK 
response is also unknown. Prolonged nutrient depriva-
tion in patients with anorexia nervosa is associated with 
an increase in plasma CCK [57]. Accordingly, we 
anticipated that early, rather than delayed, enteral 
nutrition in the critically ill may attenuate CCK secretion 
and improve feed tolerance. A shorter (<1 day) period 
neither blunted an increase in CCK concentration or 
accelerated gastric emptying, however, when compared 
with a longer (4 day) period of nutrient deprivation in 
critically ill patients [58].
Peptide YY
Peptide YY (PYY) is secreted predominantly from the 
colon and rectum, and, to a lesser extent, from the 
pancreas, distal small intestine and stomach [59]. Fat is 
the most potent stimulant of PYY secretion [59,60]. 
Plasma PYY concentrations increase within 15 minutes 
of a meal [60], suggesting that an indirect neural or 
hormonal response is responsible for initial stimulation, 
with peak concentrations occurring at ~1 hour [60]. CCK 
may mediate the initial PYY secretion, with subsequent 
direct intraluminal stimulation causing sustained PYY 
secretion [60]. Pharmacological doses of PYY slow gastric 
emptying and small-intestinal transit [61], and endoge-
nous PYY is likely to modulate gastric emptying in health. 
Exogenous PYY also inhibits appetite, and these 
ano rectic  eﬀ   ects have encouraged the investigation of 
PYY as a weight-loss therapy [62].
In an observational study of seven critically ill patients, 
Nematy and colleagues reported that fasting PYY 
concen  trations were increased approximately threefold 
in the acute phase of critical illness, when compared with 
health [32]. Moreover, we reported that fasting plasma 
PYY concentrations in 39 critically ill patients     were 
increased substantially in those that had delayed gastric 
emptying (Figure 3) [55]. Our group has also shown that 
the PYY response to small-intestinal nutrient infusion is 
exaggerated in the critically ill when compared with 
health [54]. Animal models of sepsis suggest that PYY 
concentrations increase rapidly following systemic 
infection [63]. Like CCK, endogenous PYY secretion is 
increased; and if receptor sensitivity remains unchanged, 
both hormones are candidate mediators to slow gastric 
emptying in the critically ill. PYY concentrations have 
been shown to progressively normalise as the clinical 
condition improves.
Glucagon-like peptide-1
Th   e so-called incretin eﬀ  ect refers to the greater insulino-
tropic response to an oral glucose load, as compared with 
an isoglycaemic intravenous infusion [64]. Glucagon-like 
peptide (GLP)-1 is one of the two known incretin 
hormones, and is secreted from intestinal L cells (which 
are located primarily in the distal ileum and colon) in 
response to luminal fat, carbohydrate and protein [65]. 
Studies using the speciﬁ  c GLP-1 antagonist, exendin (9-39) 
amide, have established that endogenous GLP-1 lowers 
fasting glycaemia and attenuates postprandial glycaemic 
Figure 3. Relationship between rate of gastric emptying and fasting cholecystokinin and peptide YY concentrations. Relationship between 
the rate of gastric emptying (measured using an isotope breath test and calculated as the gastric emptying coeffi   cient (GEC); greater number, more 
rapid emptying) and (a) fasting cholecystokinin (CCK) concentrations (r =   –0.33; P = 0.04) and (b) fasting peptide YY (PYY) concentrations (r = –0.36; 
P =0.02) in 39 critically ill patients. Reproduced with permission from [55].
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gastric emptying, as well as increased insulin and 
decreased glucagon secretion [66-68].
Pharmacological doses of GLP-1 reduce both fasting 
and postprandial glycaemia [69,70]. Importantly, the 
eﬀ   ects of exogenous GLP-1 to stimulate insulin and 
suppress glucagon are glucose dependent, and thus the 
risk of hypoglycaemia is not increased substantially, even 
with pharmacological dosing [71]. Furthermore GLP-1 in 
pharmacological doses appears to slow gastric emptying, 
which contributes substantially to the glucose-lowering 
eﬀ  ect [72]. Animal and human studies suggest that exo-
ge  nous GLP-1 inhibits fasting je    junal motility [73,74], 
which is anticipated to slow small-intestinal transit. 
Th  ere are signiﬁ  cant extra-gastrointestinal and islet cell 
eﬀ  ects of exogenous GLP-1, with the potential cardio-
protective eﬀ  ects of speciﬁ  c interest to the critically ill 
cohort [75,76].
In non-intensive care unit inpatients receiving total 
parenteral nutrition, Nauck and colleagues established 
that pharmacological doses of GLP-1 have the capacity to 
lower glycaemia [77]. Subsequently, Meier and colleagues 
reported that in type 2 diabetic patients after major 
surgery an acute infusion of GLP-1 reduces fasting glucose 
[78]. Recently, GLP-1 has also been reported to lower 
peri  operative glycaemia in cardiac surgical patients 
[79,80]. Given its inherent safety proﬁ  le yet substantial 
eﬀ  ects on gastrointestinal motility, we studied the eﬀ  ects 
of exogenous GLP-1 (1.2 pmol/kg/min) in nondiabetic 
critically ill patients, and established that GLP-1 
markedly attenuates the glycaemic response to small-
intes  tinal nutrition (Figure 4) [81]. In critically ill patients, 
however, enteral nutrient is delivered predominantly via 
the intragastric route and marked slowing of gastric 
emptying may be undesirable. Accordingly, we evaluated 
the eﬀ  ects of exogenous GLP-1 on gastric emptying of an 
intragastric meal [82]. While an acute infusion of GLP-1 
(1.2  pmol/kg/min) slowed gastric emptying when the 
latter was relatively normal (and     to thereby contribute to 
glucose lowering), no eﬀ  ect was evident when emptying 
was already delayed [82].
Glucose-dependent insulinotropic peptide
Th   e other known in    cretin hormone is glucose-dependent 
insulinotropic peptide (GIP) – which is secreted from 
duodenal K cells [83], primarily in response to luminal fat 
and carbohydrate [84]. GIP is markedly insulinotropic, 
but in contrast to GLP-1, it has no entero  gastrone eﬀ  ect 
(that is, it has no eﬀ  ect on either gastric acid secretion or 
gastric emptying). In addition, GIP is glucagonotropic 
during euglycaemia, and has a substantially diminished 
insulinotropic eﬀ  ect in type 2 diabetic patients [85].
Small-intestinal nutrient is recognised to stimulate GIP 
secretion in the critically ill [86], but the magnitude of 
GIP response when compared to secretion in healthy 
subjects has not been evaluated. Likewise the pharma  co-
logical eﬀ  ects of GIP in the critically ill are unknown.
Glucagon-like peptide-2
GLP-2 is co-secreted (with GLP-1) from L cells in 
response to luminal nutrient [87]. GLP-2 receptors are 
morphologically similar to the other proglucagon 
products (GLP-1, GIP) and are present in the stomach, 
small bowel, colon, lung and brain [88].
Figure 4. The eff  ect of glucagon-like peptide-1 on glycaemia in critically ill patients. In a cross-over study, exogenous glucagon-like peptide 
(GLP)-1 (1.2 pmol/kg/min) markedly attenuated the overall glycaemic response to intraduodenal nutrient infusion. Area under the curve30–270 min: 
GLP-1, 2,077 ± 144 mmol/l/min vs. placebo, 2,568 ± 208 mmol/l/min; n = 7; ***P <0.05. Reproduced from [81].
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[88]. Furthermore, in contrast to GLP-1, the peptide is 
glucagonotropic and has no eﬀ  ect on insulin secretion 
[89]. Despite the islet cell eﬀ  ects, postprandial glycaemia 
is unaﬀ  ected by exogenous GLP-2 [89]. Animal models 
have consistently demonstrated that GLP-2 in pharmaco-
logical doses potently stimulates intestinal growth, 
enhances absorptive function and improves mesenteric 
blood ﬂ  ow, thereby protecting the intestinal mucosa from 
injury [90,91]. Th  ere have been preliminary reports of 
beneﬁ  cial  eﬀ   ects using both GLP-2, and its analogue, 
teduglutide, in patients with   short-bowel syndrome 
[92,93]. Th  e physio  logical concentrations and/or eﬀ  ects 
of pharma  co  logical infusions of GLP-2 remain to be 
studied in the critically ill.
Clinical implications and future research directions
Further studies of the physiological eﬀ   ects of these 
hormones in the critically ill are indicated. It would be 
desirable to determine the basal and nutrient-stimulated 
concentrations of motilin, as well as the proglucagon 
products (that is, GLP-1, GIP and GLP-2) in this group. 
In addition, an improved understanding of the mecha-
nism(s) of increased or decreased hormone concen-
trations in this heterogeneous group would be of beneﬁ  t.
Given the association between the rate of gastric 
emptying with hormone (CCK and PYY) concentrations, 
the use of speciﬁ   c antagonists is appealing in certain 
circum  stances; for example, the CCK antagonist, 
loxiglumide, is a novel therapy that may prove to be a 
useful prokinetic in the critically ill. A potential concern 
is that CCK antagonists may also modify pancreatic 
exocrine function and, thereby, nutrient absorption. 
Accord  ingly, the absorption of nutrient should be 
assessed in studies of CCK antagonist use. A speciﬁ  c 
group of critically ill patients who warrant study using 
one of these agents is those with severe acute pancreatitis. 
CCK analogues have the capacity to induce acute pan-
creatitis in humans [94]. Furthermore, studies of 
treatment with CCK antagonists in animal models of 
pancreatitis as well as in patients with chronic pancrea-
titis have reported beneﬁ  ts [94,95].
Studies of the eﬀ  ects of physiological replacement, or 
pharmacological doses, of several of these hormones may 
also be worthwhile. Exogenous ghrelin, and/or its ana-
logues, are potential therapies to accelerate gastric 
empty  ing in patients with delayed gastric emptying and 
ileus, and/or to stimulate appetite after prolonged critical 
illness. Th   e use of ghrelin also has the potential to cause 
adverse eﬀ   ects in the critically ill, however, because 
ghrelin is the ligand for the growth hormone 
secretagogue receptor. While critical illness is associated 
with suppressed growth hormone secretion, trials with 
supra-physiological growth hormone replacement have 
reported adverse outcomes [96]. Despite the adverse 
eﬀ   ects reported in studies of pharmacological growth 
hormone, careful evaluation of the eﬀ  ects of short-term 
(7 to 21 days) treatment with ghrelin, or an analogue, to 
establish the eﬀ  ects on gastric emptying and/or appetite 
in the critically ill is indicated. Th   e motilin receptor also 
represents a target for therapy in the critically ill. 
Concerns of erythromycin-associated adverse events, 
including the potential to induce antibiotic resistance, 
have limited the general use of motilides for feed 
intolerance [97]. Accordingly, there is a need to assess the 
eﬃ   cacy of nonantibiotic motilides – which have shown 
some promise in accelerating gastric empty  ing in healthy 
individuals and ambulant patients [6].
Incretin-based therapies are likely to ﬁ  nd a place in the 
management of hyperglycaemia in the intensive care 
unit, whether associated with type 2 diabetes or stress-
induced diabetes. As discussed, a potential advantage is 
that pharmacological GLP-1 does not appear to increase 
the risk of hypoglycaemia substantially [71] and, as such, 
the peptide may be infused on a continuous basis without 
the necessity to titrate the dose [98]. In addition, aﬀ  ecting 
both insulin and glucagon may attenuate the variability in 
glycaemia when using GLP-1 compared with insulin 
therapy. To date we have evaluated the eﬀ   ects of the 
synthetic peptide to establish proof of concept. It should 
be recognised that the peptide is, currently, prohibitively 
expensive for routine clinical use. Th  ere may well be a 
substantial reduction in cost of the peptide, however, 
should a market become available.
Alternatively, GLP-1 analogues (resistant to dipeptyl-
peptidase-4 degradation) that are currently available for 
management of glycaemia in ambulant patients with type 
2 diabetes may prove useful. While more aﬀ  ordable, 
these agents (such as exenatide and lir    ag    lutide) have 
potential disadvantages, including unpredictable plasma 
concentrations in the critically ill, as well as antibody 
formation, which require evaluation [99]. Further to 
evalu  ating the eﬀ   ects of the individual proglucagon 
products (that is, GLP-1, GLP-2 and GIP), the use of 
dipeptyl-peptidase-4 inhibit    ion to increase endogenous 
concentrations of all three peptides also merits 
evaluation. As described, profound eﬀ   ects on gastric 
emptying and/or small-bowel transit are almost certainly 
undesirable,  a   nd  the  eﬀ  ects of exogenous GLP-1 on the 
gastrointestinal tract during prolonged administration in 
the critically ill should be examined. Th   e potential for an 
increased risk of gastro  esophageal reﬂ  ux, and consequent 
aspiration, and the eﬀ   ects on nutrient delivery and 
absorption represent priorities for future studies.
GIP is probably the dominant incretin in health, does 
not slow gastric emptying and has the potential to cause 
weight gain [85]. Accordingly, GIP may have a more 
desirable proﬁ  le than GLP-1. However, the insulinotropic 
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well as ~50% of their ﬁ   rst-degree relatives [100]. Th  e 
reduction in insulinotropic eﬀ  ect is due, at least in part, 
to the eﬀ  ects of hyperglycaemia. Whether a proportion 
of patients with stress-induced hyperglycaemia will 
likewise be nonresponsive to GIP pharmacotherapy, 
thereby limiting its use to speciﬁ  c patients, remains to be 
determined.
GLP-2 has potential as a therapy to stimulate intestinal 
growth and improve nutrient absorption in the critically 
ill. Furthermore, GLP-2 may reduce secondary infections 
in the critically ill, given that GLP-2 decreased trans-
location of bacteria in a rat model of acute necrotising 
pancreatitis [101]. While previous therapies targeting 
luminal immune modulation have been successful in 
animal studies but unsuccessful in human critical illness 
trials [102], GLP-2 warrants evaluation as a potential 
therapy in speciﬁ  c subgroups of patients.
Conclusions
Th   e secretion of a number of gastrointestinal hormones 
is disordered in the critically ill, and may mediate ab-
normalities in luminal motility and, potentially, changes 
in absorption, metabolism and immunity in this group. 
Treating disordered hormone secretion (with manipu-
lation of endogenous secretion, speciﬁ  c  antagonists, 
exogenous infusion of hormones, or their analogues) 
represents a novel therapeutic approach that warrants 
evaluation, and has the potential to lead to improved 
outcomes in critically ill patients.
Abbreviations
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